Back to Results

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response or are Intolerant to Biologic DMARD Therapy

Study category: Bones, Muscles, and Joints

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Eligibility

Male or female who are 18 years of age or older Has a history consistent with Psoriatic Arthritis (PsA) 6 months or more at screening Have active PsA = 3 more more swollen joints and 3 or more tender joints at screening and Day 1 Must have documented history or active signs of at least one of the following at Screening a) Plaque psoriasis b) Nail changes attributed to psoriasis

Phase

III - Research Studies that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.

Type of Study

Treatment

Locations

Barbara Davis Center
University of Colorado Hospital

Principal Investigator
Christopher Striebich

Christopher Striebich

Study ID

Protocol Number: 19-2534

More information available at ClinicalTrials.gov: NCT04115839

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers